Your browser doesn't support javascript.
loading
Effect of early adverse events resulting in ado-trastuzumab emtansine dose adjustments on survival outcomes of HER2+ advanced breast cancer patients.
Tang, Ethan; Rowland, Andrew; McKinnon, Ross A; Sorich, Michael J; Hopkins, Ashley M.
Afiliación
  • Tang E; College of Medicine and Public Health, Flinders University, Flinders Drive, Bedford Park, Adelaide, SA, 5042, Australia. tang0257@flinders.edu.au.
  • Rowland A; Flinders Medical Centre, Room 5D317, Bedford Park, SA, 5042, Australia. tang0257@flinders.edu.au.
  • McKinnon RA; College of Medicine and Public Health, Flinders University, Flinders Drive, Bedford Park, Adelaide, SA, 5042, Australia.
  • Sorich MJ; College of Medicine and Public Health, Flinders University, Flinders Drive, Bedford Park, Adelaide, SA, 5042, Australia.
  • Hopkins AM; College of Medicine and Public Health, Flinders University, Flinders Drive, Bedford Park, Adelaide, SA, 5042, Australia.
Breast Cancer Res Treat ; 178(2): 473-477, 2019 Nov.
Article en En | MEDLINE | ID: mdl-31399933
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptor ErbB-2 / Antineoplásicos Inmunológicos / Ado-Trastuzumab Emtansina Tipo de estudio: Prognostic_studies Límite: Female / Humans Idioma: En Revista: Breast Cancer Res Treat Año: 2019 Tipo del documento: Article País de afiliación: Australia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptor ErbB-2 / Antineoplásicos Inmunológicos / Ado-Trastuzumab Emtansina Tipo de estudio: Prognostic_studies Límite: Female / Humans Idioma: En Revista: Breast Cancer Res Treat Año: 2019 Tipo del documento: Article País de afiliación: Australia